Tag Archives: Sosei Group Corporation

April, 2016

25 April
Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-Based Design for Metabolic Disease

Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that its scientists have solved the high-resolution X-ray crystal structures of the GLP-1 (glucagon-like peptide 1) and glucagon receptors. Both receptors play important roles in the management of blood glucose levels and are considered to …
Share

2 December
Pfizer Enters GPCR-Based Therapy Deal with Heptares

TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. (NYSE: PFE) to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas. Heptares will …
Share